Antiretroviral Therapy

A monoclonal antibody was shown to speed the time to viral suppression in heavily treatment-experienced people with HIV compared with ART regimens that did not contain it, according to a study.

During the early rollout of dolutegravir in South Africa, women were less likely to receive the new treatment than men, despite dolutegravir being associated with improved outcomes, researchers found.

Roughly 20 million people with HIV in 54 countries are receiving ART through the President's Emergency Plan for AIDS Relief, a 300-fold increase in 2 decades, according to a new report.

Russia’s 2022 invasion of Ukraine has worsened the spread of HIV in the region as thousands of war refugees migrate to neighboring countries, according to the studies.

SEATTLE — Doravirine was noninferior at maintaining viral suppression in people with HIV through 48 weeks when compared with bictegravir/emtricitabine/tenofovir alafenamide, as well as baseline ART.

Women with HIV who had greater cumulative viremia had an increased risk of multimorbidity and developing five vascular-related non-AIDS comorbidities, according to a recent study.

Rates of both individual mutations and clinically relevant transmitted drug resistance were low among people newly diagnosed with HIV who were not previously on ART, according to a recent study.

The FDA announced approval of lenacapavir, a new antiretroviral medication for adults with HIV type 1 who cannot be treated with other therapies because of resistance, intolerance or safety concerns.

The International Antiviral Society–USA Panel recently published new recommendations for managing HIV, including when to start therapy and which treatment regimens to use.

In Tanzania, pregnant women with HIV who had access to antiretroviral therapy for life had less than a 2% risk for vertical transmission, according to data published in The Lancet HIV.